Citations

Clear

904 citation(s) found for "Gordon, S".

Poster Session II - A221 A SYSTEMATIC REVIEW OF DEFINITIONS AND DIAGNOSIS OF CROHN’S DISEASE COLONIC STRICTURES
Lu, C, Dhaliwal, R, Kellar, Amelia , Rowan, Catherine , St-Pierre, J, Suarez, K E, O’Brien, M, Rosentreter, R E, Gulhati, Vishrut, Baker, M E, Bruining, D, Fletcher, J, Gordon, I, Jairath, V, Feagan, B, Rieder, F, Lu, C, Dhaliwal, R, St-Pierre, Joelle, O’brien, M, Rosentreter, Ryan E., Baker, Mark E. , Bruining, David H. , Fletcher, Joel G. , Feagan, B G

Mayo Clinic

Journal of the Canadian Association of Gastroenterology | February 13, 2026 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1093/jcag/gwaf042.220 Get It

Abstract Background Colonic strictures in Crohn’s disease (CD) are an important, but understudied clinical problem. Cross-sectional imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and intestinal ultrasound (IUS) effectively assess the small bowel in CD allowing for the diagnosis of strictures. However, radiologic definitions of colonic strictures and their diagnostic accuracy have not been developed. Endoscopic definitions of colonic strictures are the most well-described. Aims We aimed to systematically review available data to summarize definitions, diagnosis and differentiation between inflammation and fibrosis of colonic strictures on endoscopy, CT, MR, and IUS Methods We conducted a systematic review following PRISMA guidelines using MEDLINE, Scopus, CINAHL, and CENTRAL databases from inception to Oct 6, 2024 to identify literature with diagnostic imaging that included patients with colonic CD strictures. To distinguish fibrosis from inflammation, only studies comparing endoscopy or imaging to a full thickness histologic gold standard were included. Two stage screening was completed in duplicate, and risk of bias was assessed using QUADAS-2 Results 46 studies were eligible for inclusion. Definitions for colonic strictures on CT, MR, and IUS are heterogeneous with combinations of bowel wall thickness, luminal narrowing, and pre-stenotic dilation with no clear cut offs. Endoscopic definitions commonly included lack of colonoscope passage through a narrowed lumen. The diagnostic accuracy of colonic strictures on imaging to detect inflammation and fibrosis against a gold standard of endoscopy or surgical resection is unclear as direct comparisons are few. Meta-analyses were not conducted due to methodological heterogeneity of grading fibrosis and statistical heterogeneity of sensitivity, specificity, and accuracy of colonic stricture diagnoses limited by pooling with small bowel strictures in the studies Conclusions This systematic review describes a lack of definitions for the diagnosis of CD colonic strictures particularly on diagnostic imaging, and the limitations with the current available data to differentiate inflammation from fibrosis. Although bowel wall thickening, luminal narrowing, and pre-stenotic dilation are recognized as hallmark features of small bowel strictures, their adaptation to the colon requires further assessment. Definitions for colonic strictures should likely include imaging combined with endoscopy. Future endeavors are required to develop a consensus to define and diagnose colonic strictures on these modalities Funding Agencies None
Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology
Advani, Ranjana H., Kelsey, C., Armand, Philippe, Bello, Celeste, Benitez, Cecil M. , Chen, Weina , Cherian, Sheen , Czader, Magdalena , Dabaja, Bouthaina, Daly, Megan E., Gordon, L. I., Hansen, Neil, Herrera, Alex F. , Hochberg, Ephraim P. , Hoppe, Richard T., Isufi, Iris, Johnston, Patrick B., Kelly, Kara M, Kenkre, Vaishalee P. , Lynch, R., Morgan, David, Rabinovitch, R., Salavati, Ali, Sano, Dahlia , Svoboda, J., Yahalom, Joachim, Yang, Joanna C. , Stehman, Katie, Advani, Ranjana H. , Hoppe, Richard T. , Advani, Ranjana H , Hoppe, Richard T , Kelsey, Chris R. , Armand, Philippe , Bond, David A. , Dabaja, Bouthaina, Daly, Megan, Frosch, Zachary AK , Hansen, Neil, Johnston, Patrick B, Kelly, Kara M , Kline, Justin Paul , McConathy, Jonathan , Niu, Alex , Paul, Suman , Rabinovitch, Rachel , Salavati, Ali , Shah, Harsh , Spinner, Michael A. , Svoboda, Jakub , Winter, Jane N. , Yahalom, Joachim , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 9, 2026 | Volume: 24 | Issue: 2 | Pages: 41-60

10.6004/jnccn.2026.0006 | PMID 41671432 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hodgkin lymphoma provide expert, multidisciplinary recommendations for the diagnosis and treatment of Hodgkin lymphoma. The panel convenes annually to update recommendations based on a review of recently published clinical trials. This selection from the NCCN Guidelines for Hodgkin Lymphoma focuses on the management of newly diagnosed and relapsed/refractory classic Hodgkin lymphoma in adults aged 18 to 60 years.
Genome and Transcriptome-Wide Analyses Identify Multiple Candidate Genes and a Significant Polygenic Contribution in Bicuspid Aortic Valve
Thériault, Sébastien , Holdcraft, Jacob A., Sharipova, Dinara , Dębiec, Radosław , Peloso, Gina M., Al‐Kassou, Baravan , Swan, Elena Ashikhmina , Ballotta, Andrea, Björck, Hanna M. , Braund, Peter S. , Corriveau, François, Dagenais, François, Francke, Michael, Gorbatov, Svetlana, Guo, Dongchuan, Habchi, Karam M, Scouarnec, Solena Le , Lichtner, Peter , Nguyen, Thy B., Norris, R., Pibarot, P, Simonet, Floriane, Tm, Sundt, Tessler, Idit , Willer, Cristen J., Wittmann, Susanne, Yang, Bo, Berezovets, Igor, Doppler, S. , Dreßen, Martina, Knoll, Katharina, Puehler, T., Schunkert, H, Bissell, Malenka M. , Bolger, Aidan, Brion, M, Citro, Rodolfo, Deeb, G. Michael, Corte, Alessandro Della, Dina, C., Eriksson, Per, Evangelista, Arturo , Franco-Cereceda, Anders, Gilon, Dan, Hetherington, Simon, Huggins, G S, Krane, Markus , Tourneau, Thierry Le, Limongelli, Giuseppe, Mathieu, P., Messika-Zeitoun, David, Michelena, Hector I., Milewicz, Dianna, Murdock, David R. , Nickenig, G., Nistri, Stefano, Nöthen, M, Samani, Nilesh J. , Schott, J., Webb, Tom R., Abdelilah-Seyfried, Salim, Schumacher, Johannes, Trenkwalder, Teresa , Body, Simon C. , Dina, Christian , Brión, Marı́a , Peloso, Gina M. , Webb, Tom R. , Faucherre, Adèle , Debiec, Radoslaw M , Peloso, Gina M , Al-Kassou, Baravan , Aranki, Sary , Ashikhmina Swan, Elena , Björck, Hanna M , Boureau, Anne Sophie , Braund, Peter S , Folkersen, Lasse , Guo, Dongchuan , Heydarpour, Mahyar , Isselbacher, Eric M , Jopling, Chris , Laporte, Fabien , Le Scouarnec, Solena , Li, Zhonglin , Lichtner, Peter , Maj, Carlo , Manikpurage, Hasanga D , Nguyen, Thy B , Norris, Russell A , Pibarot, Phillippe , Sarubbi, Berardo , Simonet, Floriane , Sundt, Thoralf , Surakka, Ida , Tessler, Idit , Yang, Bo , Doppler, Stefanie A , Dreßen, Martina , Knoll, Katharina , Puehler, Thomas , Schunkert, Heribert , Bissell, Malenka M , Bossé, Yohan , Bossone, Eduardo , Brion, María , Citro, Rodolfo , de Vincentiis, Carlo , Deeb, G Michael , Della Corte, Alessandro , Dina, Christian , Durst, Ronen , Ensminger, Stephan , Eriksson, Per , Evangelista, Arturo , Franco-Cereceda, Anders , Gilon, Dan , Giusti, Betti , Hetherington, Simon L , Huggins, Gordon S , Le Tourneau, Thierry , Limongelli, Giuseppe , Mathieu, Patrick , Messika-Zeitoun, David , Michelena, Hector I , Milewicz, Dianna M , Muehlschlegel, Jochen D , Murdock, David R , Nickenig, Georg , Nistri, Stefano , Nöthen, Markus M , Prakash, Siddharth K , Samani, Nilesh J , Jacques Schott, Jean , Webb, Tom R , Zaffran, Stéphane , Eagle, Kim , Body, Simon C , Holdcraft, Jacob A., Bellino, Michele , Dagenais, François, Forte, Amalia , Frigiola, Alessandro , Guo, Dongchuan , Isselbacher, Eric M. , Nelson, Christopher P. , Ong, Chin Siang , Roychowdhury, Tanmoy , Surakka, Ida , Willer, Cristen J , Aviérinos, Jean-François , Bolger, Aidan P. , Bossé, Yohan , Bossone, Eduardo , Citro, Rodolfo , Deeb, G. Michael , Corte, Alessandro Della , Gilon, Dan, Huggins, Gordon S. , Tourneau, Thierry Le , Mathieu, Patrick , Messika–Zeitoun, David , Nistri, Stefano , Nöthen, Markus M. , Pluchinotta, Francesca Romana , Prakash, Siddharth K. , Schott, Jean‐Jacques , Zaffran, Stéphane , Abdelilah‐Seyfried, Salim , Eagle, Kim A. , Schumacher, Johannes

Mayo Clinic

Circulation | February 6, 2026 | Volume: 153 | Issue: 14 | Pages: 1060-1076

10.1161/circulationaha.125.074752 | PMID 41645906 Get It

BACKGROUND: Bicuspid aortic valve (BAV) is a frequent congenital heart defect with a high heritability. Despite this, only a limited number of genes have been associated with the disease, and the molecular mechanisms remain unexplained in most cases. This study aimed to further understand the genetic architecture of BAV. METHODS: A genome-wide association study meta-analysis including 9631 cases among 65 677 participants was performed. Genes were prioritized using transcriptomic analyses based on RNA sequencing in relevant tissues, including human fetal and adult aortic valves. The impact of the knockdown or knockout of 4 candidate genes on cardiac development was verified in zebrafish. A polygenic risk score was developed, its association with BAV was evaluated in an independent cohort, and its association with a wide range of phenotypes (n=976) was evaluated in UK Biobank (n=355 618 individuals). RESULTS: Thirty-six genomic loci were identified, including 32 that were not described previously. Among the prioritized genes, KANK2 and ERBB4 were identified as potentially causal through transcriptomic analyses, colocalization, and Mendelian randomization based on gene expression in human aortic valves (n=484), whereas PRDM6 and STRN were prioritized using similar analyses from aortic (n=326) and left ventricular tissues (n=326), respectively. Targeting 4 candidate genes ( WNT4 , LEF1 , STRN , and KANK2 ) in zebrafish led to disruption in cardiac development. A polygenic risk score was associated with an odds ratio of 2.07 (95% CI, 1.90–2.25; P =5.43×10 -62 ) per SD for BAV and significantly associated with thoracic aortic aneurysm and atrial fibrillation in UK Biobank. CONCLUSIONS: This study supports a significant polygenic contribution to BAV, where the combination of multiple common variants in genes involved in heart morphogenesis disrupts aortic valve development.
MIF-CD74 signaling drives immune modulation in medulloblastoma
Draper, Benjamin, You, Zhen , Thompson, Dean, Guo, Xu, Morcavallo, Alaide , Pino, Diego Chillón, Nery, Carlos Lorenzo Gido, Shrestha, Sumana , Himsworth, Courtney , Delaidelli, A., Morlando, Sonia , Wade, Brandon, Gordon, Freya , Sanchez-Corrales, Yara, Hopkins, Bei, Monteiro, Natalie, Locke, Darren, Liu, Miao , Diaz, Jacob Torrejon, Greenslade, Kevin , Costa, Barbara Martins Da , Barker, Karen, Fletcher, Anya, Custódia, Carlos , Roque, Rafael , Jackson, Thomas, Barfoot, Regan, Castellano, Sergi , Hill, Rebecca M. , Saulnier, Olivier , Jacques, Thomas S, Faria, Claudia C , Ayrault, Olivier , Sorensen, Poul H., Anderson, John, Chesler, Louis, Huang, L Frank, Clifford, Steven C. , Castellano, Sergi , Jacques, Thomas S , Donovan, Laura K , Draper, Benjamin , Thompson, Dean , Bowers, Chantelle E , Delaidelli, Alberto , Remeniuk, Bethany , Sánchez-Corrales, Yara E. , Hopkins, Bei, Torrejon-Diaz, Jacob, Barker, Karen T. , Kwok, Colin , Ogunbiyi, Olumide Kayode , Richardson, Stacey , Jackson, Thomas John , Jacques, Thomas S. , Taylor, Michael D. , Anderson, John, Chesler, Louis , Huang, L Frank

Mayo Clinic

Neuro-Oncology | February 3, 2026 | Volume: 28 | Issue: 5 | Pages: 1316-1334

10.1093/neuonc/noag020 | PMID 41652893 Get It

Abstract Background Relapsed medulloblastoma remains a significant therapeutic challenge as it is near universally fatal. The tumor microenvironment of medulloblastoma plays a critical role in tumor progression, influencing tumor growth, immune evasion, and therapeutic resistance. We hypothesized that defining tumor-immune interactions in diagnostic and relapsed medulloblastoma may uncover mechanisms of immune evasion and identify novel therapeutic targets. Methods We analyzed paired primary and recurrent RNA-sequencing data from 140 medulloblastoma patients to profile immune cell composition and validate spatial relationships within the TME. To identify key tumor-immune interactions, we developed a novel algorithm to detect receptor-ligand pairs using single-cell RNA-sequencing data. These interactions were validated across RNA and proteomic datasets. Their functional significance was empirically demonstrated in newly developed immunocompetent models of recurrent medulloblastoma that closely recapitulate the human disease. Results We observed a shift toward a heightened immunosuppressive TME at relapse. Using our algorithm, we identified biologically significant receptor-ligand interactions, most notably MIF-CD74, constitutively expressed at RNA and protein levels across medulloblastoma subgroups, at diagnosis and relapse. Disrupting MIF-CD74 interactions led to significant alterations in the tumor microenvironment, highlighting its functional significance. Conclusions Our multifaceted approach identified key tumor-immune interactions in medulloblastoma. Among these, MIF-CD74 was validated as a targetable interaction, demonstrating the utility of our integrative approach for identifying novel therapeutic targets across multiple tumor types.
Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169
Zaidi, Samir , Kuo, Phillip H. , Prudente, Tiago Paiva, Lacuna, Kristine P. , Babiker, Hani M., Aparicio, Renan , Schonhoft, Joseph D. , Fernandez, Luisa , Messmann, Richard , Groaning, Michael , Tolcher, Anthony W., Gordon, Michael S. , Yoo, Don C. , Vaishampayan, Ulka, Petrylak, Daniel P., Sartor, Oliver, Morris, Michael J., Vaishampayan, Ulka N. , Babiker, Hani M. , Kuo, Phillip H. , Messmann, Richard A. , Lacuna, Kristine Peregrino , Paiva Prudente, Tiago , Babiker, Hani , Tolcher, Anthony W. , Vaishampayan, Ulka , Picus, Joel , Petrylak, Daniel P , Sartor, A Oliver , Morris, Michael J , Groaning, Michael D., Picus, Joel , Petrylak, Daniel P. , Morris, Michael J.

Mayo Clinic

Clinical Cancer Research | January 27, 2026 | Volume: 32 | Issue: 9 | Pages: 1766-1776

10.1158/1078-0432.ccr-25-2313 | PMID 41591990 Get It

Abstract Purpose: Prostate-specific membrane antigen (PSMA)–directed therapies provide meaningful clinical benefit in metastatic castration-resistant prostate cancer (mCRPC), yet responses remain limited, underscoring the need for additional biomarkers of PSMA expression heterogeneity. In this study, we explored the relationship between PSMA imaging and PSMA expression on circulating tumor cells (CTC) in our early-phase trial using a PSMA-targeted small molecule. Experimental Design: This phase I study investigated EC1169, a small molecule conjugated to a tubulysin analog warhead, and 99mTc–EC0652, a PSMA imaging agent. Part A (dose escalation) identified the recommended phase II dose. Part B (dose expansion) assessed radiographic progression-free survival (rPFS) as its primary endpoint. We enrolled and treated 103 patients with mCRPC. Most part B patients underwent 99mTc–EC0652 PSMA imaging. A CTC assay assessed PSMA-positive CTCs and their association with response and PSMA imaging. Results: 99mTc–EC0652 single-photon emission computed tomography (SPECT) imaging demonstrated increased sensitivity for detecting bone lesions compared with standard scans (computed tomography/bone scans). Using an optimized CTC assay, we observed that patients with a decrease in PSMA+ CTCs at baseline versus C3D1 displayed a longer rPFS (8 vs. 2.9 months; P = 0.04). Importantly, patients with predominantly PSMA-positive disease on 99mTc–EC0652 imaging also harbored PSMA-negative CTCs, with a subset displaying neuroendocrine prostate cancer–like morphology. Conclusions: Although EC1169 showed limited activity, CTC and imaging analyses showed significant heterogeneity in PSMA expression on CTCs in patients with predominantly PSMA-positive lesions on SPECT. Our study highlights the importance of assessing both PSMA-based CTC and imaging assays in future validation trials.
Assessing Braak stage agreement between four Tau PET tracers
Rocha, Andreia, Bellaver, Bruna, Soares, Carolina, Ferreira, Pamela C.L., Madeiros, Marina Scop, Povala, Guilherme, Amaral, Lívia , Lussier, Firoza Z, Mroué, Rayan, Masdeu, Joseph C., Tudorascu, Dana L, Soleimani‐Meigooni, David N., Fortea, Juan M., Lowe, VJ, Oh, Hwamee, Pascual, Belen, Gordon, Brian A., Rosa‐Neto, Pedro, Baker, Suzanne L. , Pascoal, Tharick A, Medeiros, Marina Scop , Rocha, Andreia, Bellaver, Bruna , Soares, Carolina , Ferreira, Pâmela C.L. , Ruppert, Emma Patrice , Madeiros, Marina Scop, Povala, Guilherme , Bauer‐Negrini, Guilherme , Lussier, Firoza Zubeida , Rodrigues, Matheus Scarpatto , Masdeu, Joseph C , Tudorascu, Dana , Soleimani‐Meigooni, David N. , Fortea, Juan , Oh, Hwamee , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 22, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_107635 | PMID 41570193 Get It

Abstract Background The Alzheimer's disease (AD) Braak staging is a key framework for classifying tau pathology progression in AD based on histopathological post‐mortem brain examinations. However, adapting it to PET imaging can be challenging due to differences in tracer uptake patterns and binding properties, which affect sensitivity, specificity, and regional staging. This study compares Braak staging across four tau PET tracers: Flortaucipir, MK6240, PI2620, and RO948. Methods We assessed 90 participants across the AD spectrum (46 CU, 31 MCI, 13 dementia; mean age 66.1 ± 7.8) using Aβ PET and four tau PET tracers: (Flortaucipir, MK6240, PI2620, and RO948). Braak positivity was defined based on Aβ− CU individuals (mean +2.5 SD, SUVR). To evaluate systematic bias and agreement between tracers, we computed pairwise differences at corresponding Braak stage estimates and applied the Bland‐Altman method to assess mean bias and limits of agreement. Additionally, Tau PET Braak region trajectories were modeled as functions of Aβ burden (Centiloid scale) using the Lowess method. Results Braak stage trajectories as a function of Aβ differ depending on the tracer and the sequential order of abnormality is highly variable. For instance, while for MK6240, RO948 and PI2620, Braak I is the first region to became abnormal, for Flortaucipir the earliest region to became abnormal is Braak IV (Figure 1). This variable pattern of abnormality impacts in the concordance of Braak staging between tracers with the highest Braak staging agreement resulting in concordance levels of approximately 70%. The highest levels of agreement between tracers usually happen at Braak 0 or Braak IV‐V, with intermediate stages showing very low concordance (Figure 2). The Bland‐Altman analysis identified wide limits of agreement, suggesting high variability and high tracer‐specific differences (Figure 3). On the other hand, it also identified that mean differences between tracers were small, indicating minimal systematic bias. Conclusion These preliminary findings reveal discrepancies in Braak staging when comparing Flortaucipir, MK6240, PI2620 and RO948. These findings suggest that while the tracers provide comparable stages on average, they may not be fully interchangeable in individual cases.
P0296 Definitions and diagnosis of benign Crohn’s Disease associated colonic strictures: A systematic review
Lu, C, Dhaliwal, R, Kellar, Amelia , Rowan, Catherine , St-Pierre, J, Ernest-Suárez, K, O’brien, M, Rosentreter, Ryan E., Gulhati, Vishrut, Baker, Mark E. , Bruining, D, Bari, D, Dillman, J, Ouali, S El, Fletcher, J, Gordon, I, Jairath, V, Feagan, B G, Rieder, F, St-Pierre, Joelle, Ernest-Suárez, Kenneth , Bettenworth, Dominik , Bruining, David H. , Dillman, Jonathan R , Ouali, Sara El , Fletcher, Joel G. , Gordon, I, Jairath, Vipul , Feagan, B G, Rieder, Florian

Mayo Clinic

Journal of Crohn’s and Colitis | January 21, 2026 | Volume: 20 | Issue: Supplement_1 | Pages: No page available

10.1093/ecco-jcc/jjaf231.477 Get It

Abstract Background Colonic strictures in Crohn’s disease (CD) present a complex and relatively underexplored clinical issue. Imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and intestinal ultrasound (IUS), have established criteria for evaluating small bowel CD strictures. However, radiologic definitions of benign colonic strictures and their diagnostic accuracy are not well-developed. Endoscopic definitions of colonic strictures are the most well-described. We conducted a systematic review to summarize definitions, diagnosis, and identification of inflammation and fibrosis of colonic strictures on endoscopy, CT, MR, and IUS. Methods A systematic review following PRISMA guidelines, from inception to October 6, 2024, was conducted using MEDLINE, Scopus, CINAHL, and CENTRAL databases to identify literature on diagnostic imaging of patients with colonic CD strictures. Only studies with comparison to endoscopy or imaging to a full-thickness histologic gold standard to differentiate fibrosis from inflammation were included. Two stage screening was completed in duplicate, and risk of bias was assessed using QUADAS-2. Results 46 studies were eligible for inclusion of 4623 abstracts screened. Definitions of colonic strictures on CT, MR, and IUS were highly variable with combinations of bowel wall thickness, luminal narrowing, and pre-stenotic dilation. Endoscopic definitions of colonic strictures were the most consistently reported as lack of passage of a colonoscope through a narrowed lumen. Diagnostic imaging definitions used various combinations of increased bowel wall thickness, luminal narrowing, and pre-stenotic dilation with no clear cutoffs. Few studies directly compared imaging features with histologic or endoscopic gold standards, limiting evaluation of diagnostic accuracy. Meta-analyses were not conducted due to methodological heterogeneity of grading fibrosis across studies. In addition, statistical heterogeneity of sensitivity, specificity, and accuracy of colonic stricture diagnoses was limited by pooling with small bowel strictures in the studies. Conclusion This systematic review highlighted the absence of standardized definitions for diagnosing colonic Crohn’s disease strictures, particularly on diagnostic imaging, and the limited data distinguishing inflammatory from fibrotic components. Bowel wall thickening, luminal narrowing, and pre-stenotic dilation are key features of small bowel strictures, but their relevance to the colon requires further assessment. Establishing standardized definitions for colonic strictures that incorporate both endoscopic and imaging modalities is essential to advancing the field. Conflict of interest: Dr. Lu, Cathy: Advisory board - Abbvie, Johnson and Johnson, Takeda, Ferring, Merck, Celltrion, Lilly, Pfizer, Pendopharm, Agomab. Research Funding - Abbvie, Helmsley Charitable Trust, Alberta Innovates Dhaliwal, Ravdip: No conflict of interest Kellar, Amelia: No conflict of interest Rowan, Catherine: No conflict of interest St-Pierre, Joelle: Consultant for Pfizer, Abbvie, Eli Lilly and Pendopharm, and speaker for Takeda. Ernest-Suárez, Kenneth: Consulting/Advisory Board fees: Abbvie, AstraZeneca, Johnson & Johnson, Pfizer, Ferring, Sandoz, SatisfAI, Takeda O’Brien, Maureen: No conflict of interest Rosentreter, Ryan: No conflict of interest Gulhati, Vishrut: No conflict of interest Baker, Mark: No conflict of interest Bettenworth, Dominik: DB is on the advisory board or consultant for AbbVie, Amgen, Arena, Atheneum, BNG Service GmbH, Bristol Myers Squibb, CED-Service GmbH, Celltrion, Doctorflix, DGVS, Diaplan, Else Kröner-Fresenius Foundation, Falk Foundation, Galapagos, Guidepoint, Impulze, Ferring, Janssen Cilag, Lilly, Medical Tribune, MedTriX, MSD, Mylan, Onkowissen, Pharmacosmos, Pfizer, Roche, Sandoz, Takeda, Tetrameros, Thieme, Tillotts Pharma, UCB Biopiharma, Viatris and Vifor Pharma. Bruining, David: Advisory board fees from Janssen Bari, Dane: Grant from Helmsley Charitable Trust speaker honorarium from Siemens Healthineers support for attending meetings or travel from Siemens Healthineers member of the Olympus advisory board co-chair Society of Abdominal Radiology (SAR) Inflammatory Bowel Disease Disease Focused Panel (IBD DFP) and SAR Photon-Counting Detector CT Emerging Technology Commission and chair of the Society for Advanced Body Imaging Scientific Committee. Dillman, Jonathan: Grants from Philips Healthcare, GE HealthCare, Motilent, Perspectum, Guerbet, and Bracco. El Ouali, Sara: Speaker and/or consulting fees from Takeda, Eli Lilly, Janssen, Abbvie. Fletcher, John: Grant supports from Siemens Healthineers Gordon, Ilyssa: Grants to institution from Morphic Therapeutics, Alimentiv, Pliant Therapeutics, and UCB patent pending with Case Western Reserve University on radiomics signatures Jairath, Vipul: Consulting Fees: Abbvie, Alimentiv, Amgen, Anaptys Bio, Asahi Kasei, Asieris, Astra Zeneca, Attovia, Blackbird Labs, BMS, Boehringer Ingleheim, Biomebank, Caldera, Calluna, Catalytic Health, Celltrion, Ensho, Enthera, Exeliome Biosciences, Ferring, Fresenius Kabi, Gilead, Granite Bio, GSK, Janssen, Lilly, Merck, Mountainfield, MRM Health, Nxera, Organon, OSE Immunotherapeutics, Pendopharm, Pioneering Medicine, Pfizer, Prometheus, Roche/Genentech, Sanofi, SCOPE, Shattuck Labs, Sorriso, Spyre, Synedgen, Takeda, Teva, Tillotts, Union Therapeutics, Ventus, Ventyx, Vividion, Xencor, Zealand Pharma. Feagan, Brian Gordon: Consulting Fees: AbbVie, Abivax, Adaxion, Adiso, AgomAB Therapeutics, Akros, Alira Health, Ally Bridge Group, Apini Therapeutics, Argenx, Attovia Tx, Avoro Capital Advisors, Belmore Law, Biora Therapeutics, Blackbird Laboratories, Boehringer-Ingelheim, BMS, Boxer Capital, Celgene/BMS, Clarivate, Connect Biopharm, EcoR1, Eli Lilly, Ensho Therapeutics, Equillium, Evida, Enveda, Evommune Inc. Faes Farma, First Wave, Forbion, Galapagos, Genentech/Roche, General Atlantic, Genesis Therapeutics, Gerson Lehrman Group, Gilead, Guidepoint, Imhotex, ImiDomics, Immunic Therapeutics, Janssen, Japan Tobacco Inc., LifeMine Therapeutics, Mage Biologics, Merck, Mirador Therapeutics, Mobius Care, Monte Rosa Tx, Morphic Therapeutics, Nimbus Therapeutics, Novartis, Nxera, OncoC3, Palisade Bio, Pendopharm, Pfizer,Q32 Bio, REDX, Roche, Sanofi, Sobi, Sorriso, Spyre Therapeutics, Sun Pharma, Surrozen Inc., Synedgen, Takeda, Tegus Inc., Teva, Tillotts, Trex Bio, TR1X Inc. TVM Lifesciences, Ventyx Biosciences, Versant Ventures, Vida Ventures, Ysios Capital, Zagbio Stock Shareholder: Connect Biopharm, EnGene, Evida, SRT, Imidomics, Enveda Rieder, Florian: Personal Fees: Adiso, Adnovate, Agomab, Allergan, AbbVie, Arena, Astra Zeneca, Boehringer-Ingelheim, Celgene/BMS, Celltrion, CDISC, Celsius, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Granite, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis Limited, Index Pharma, Landos, Jannsen, Koutif, Mestag, Metacrine, Mopac, Morphic, Organovo, Origo, Palisade, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Sanofi, Surmodics, Surrozen, Takeda, Techlab, Teva, Theravance, Thetis, UCB, Ysios, 89Bio
GRADE Guidance: Update on Developing Good Practice Statements in Guidelines
Dewidar, Omar , Akl, Elie A, Saz-Parkinson, Zuleika, Langendam, Miranda , Meerpohl, Joerg J , Marti, Melanie, Djulbegović, Benjamin , Brignardello-Petersen, Romina, Chu, Derek, Murad, M Hassan, Canelo-Aybar, C., Alonso-Coello, Pablo, Qaseem, Amir, Schwingshackl, Lukas , Klugar, Miloslav , Comas, David Rigau, Iorio, Alfonso , Turgeon, A. F., Shamliyan, Tatyana A, Munn, Zachary, Mathioudakis, Alexander G., Piggott, Thomas , Lotfi, Tamara, Guyatt, Gordon, Schünemann, Holger J, Akl, Elie A. , Schünemann, Holger J. , Chu, Derek K. , Akl, Elie A , Saz-Parkinson, Zuleika , Langendam, Miranda W , Meerpohl, Joerg J , Marti, Melanie , Mayer, Martin , Djulbegovic, Benjamin , Brignardello-Petersen, Romina , Chu, Derek K , Canelo-Aybar, Carlos , Mathew, Joseph L , Alonso-Coello, Pablo , Qaseem, Amir , Schwingshackl, Lukas , Bognanni, Antonio , Morgan, Rebecca L , Klugar, Miloslav , Iorio, Alfonso , Turgeon, Alexis F , Munn, Zachary , Mathioudakis, Alexander G , Piggott, Thomas , Lotfi, Tamara , Pottie, Kevin , Schünemann, Holger J , Morgano, Gian Paolo , Parmelli, Elena , Brignardello‐Petersen, Romina , Murad, M Hassan , Alonso‐Coello, Pablo , Rojas, María Ximena , Morgan, Rebecca L. , Stallings, Elena , Tugwell, Peter , Darzi, Andrea J. , Shamliyan, Tatyana , Lotfi, Tamara , Pottie, Kevin

Mayo Clinic

Annals of Internal Medicine | January 19, 2026 | Volume: 179 | Issue: 3 | Pages: 430-439

10.7326/annals-25-00431 | PMID 41554128 Get It

PART characterization using MK‐6240 and Flortaucipir
Soares, Carolina, Ferreira, Pamela C.L., Madeiros, Marina Scop, Rocha, Andreia, Bellaver, Bruna, Oliveira, Markley Silva , Povala, Guilherme, Amaral, Lívia , Masdeu, Joseph C., Tudorascu, Dana L, Karikari, Thomas K, Soleimani‐Meigooni, David N., Fortea, Juan M., Lowe, VJ, Oh, Hwamee, Pascual, Belen, Gordon, Brian A., Rosa‐Neto, Pedro, Baker, Suzanne L. , Pascoal, Tharick A, Medeiros, Marina Scop , Soares, Carolina , Ruppert, Emma Patrice , Ferreira, Pâmela C.L. , Madeiros, Marina Scop, Rocha, Andreia, Rodrigues, Matheus Scarpatto , Bellaver, Bruna , Povala, Guilherme , Lussier, Firoza Zubeida , Masdeu, Joseph C , Tudorascu, Dana , Karikari, Thomas K. , Soleimani‐Meigooni, David N. , Fortea, Juan , Oh, Hwamee , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 11, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_106723 Get It

Abstract Background Older adults with brain tau pathology but no evident amyloid‐beta (A) pathology can be referred to as primary age‐related tauopathy (PART). However, in vivo characterization of PART using biomarkers remains unclear, varying based on the method used to define tau pathology (e.g. different tau‐PET tracers). Here, we conducted a head‐to‐head characterization of PART using two different tau‐PET tracers. Method We studied 433 individuals from the HEAD cohort (244 CU, 138 MCI, and 51 with dementia). Participants underwent clinical assessments, MRI, A‐PET, both MK‐6240 and Flortaucipir scans, and a subset with plasma biomarkers ( n = 332). A‐PET positivity was defined as Centiloid>24. Tau‐positivity(T) was determined by MK‐6240 and Flortaucipir SUVR values exceeding the mean+2SD in at least one Braak region anchored in CU A‐ individuals followed by visual confirmation in A‐/T+ cases. Concordance across biomarkers was assessed among PART (A‐/T+), A‐/T‐ and A+/T+ groups. Plasma GFAP, p ‐tau217, NFL levels, and Centiloids were compared across A/T groups using linear regression. Result We found a total of 25 (5.8 %) cases classified as A‐/T+ defined by at least one tau tracer (74±6.3 years, 52% females, 17 CU, 3 MCI, 5 with dementia). Detection of A‐/T+ cases varied by tracer: MK‐6240( n = 20), Flortaucipir( n = 16) (Figure 1A). Among A‐/T+ individuals, MK‐6240 identified 13 CU, 4 MCI, and 3 dementia cases, while Flortaucipir identified 11 CU, 3 MCI, and 2 dementia cases(Figure 1B). Concordance between MK‐6240 and Flortaucipir in A‐/T+ cases was low ( n = 11, 44%)(Figure 1C). A‐/T+ individuals showed no significant biomarker differences from A‐/T‐ but had lower biomarker levels than A+/T+: Centiloids (MK‐6240: T=15.08, p <0.001; Flortaucipir: T=14.36, p <0.001), GFAP (MK‐6240: T=5.04, p < 0.01; Flortaucipir: T=2.92, p <0.001), p ‐tau217 (MK‐6240: T=7.77, p <0.001; Flortaucipir: T=6.34, p <0.001), except for NFL (MK‐6240: T=1.35, p = 0.18; Flortaucipir: T=1.14, p = 0.25)(Figure 2). Representative A and tau biomarker cases (Figure 3A), along with discordant cases classified as T+ by only one tracer (Figure 3B), are illustrated. Conclusion Our preliminary analysis revealed a higher prevalence of A‐/T+ cases with MK‐6240 than Flortaucipir, low concordance between tracers and consistently lower biomarker levels in A‐/T+ compared to A+/T+. Larger studies and longitudinal analyses are necessary to ascertain the pathological trajectories of A‐/T+ individuals with varying tau biomarker profiles.
Head‐to‐Head evaluation of plasma p ‐tau217 associations with MK6240, Flortaucipir, PI2620, and RO948 tau PET tracers
Ferreira, Pamela C.L., Chan, Tevy , Bellaver, Bruna, Povala, Guilherme, Soares, Carolina, Felix, Cynthia, Rocha, Andreia, Madeiros, Marina Scop, Amaral, Lívia , Cehula, Juli, Masdeu, Joseph C., Tudorascu, Dana L, Karikari, Thomas K, Soleimani‐Meigooni, David N., Fortea, Juan M., Lowe, VJ, Oh, Hwamee, Pascual, Belen, Gordon, Brian A., Rosa‐Neto, Pedro, Baker, Suzanne L. , Pascoal, Tharick A, Medeiros, Marina Scop , Ferreira, Pâmela C.L. , Bellaver, Bruna , Povala, Guilherme , Bauer‐Negrini, Guilherme , Ruppert, Emma Patrice , Soares, Carolina , Felix, Cynthia , Rocha, Andreia, Madeiros, Marina Scop, Cehula, Juli, Lussier, Firoza Zubeida , Masdeu, Joseph C , Tudorascu, Dana , Karikari, Thomas K. , Soleimani‐Meigooni, David N. , Fortea, Juan , Oh, Hwamee , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 11, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_106115 Get It

Abstract Background Tau phosphorylation and aggregation are hallmark features of Alzheimer's disease pathology(AD). Previous studies have shown that plasma phosphorylated tau( p ‐tau) at threonine 217 can detect AD‐related tau tangle pathology. However, the head‐to‐head association between p ‐tau217 and different tau PET tracers remains unexplored. Here, we conducted a head‐to‐head comparison of the association between plasma p ‐tau217 and four distinct tau PET tracers[MK6240, Flortaucipir(FTP), PI2620, RO948]. Method We studied 338 individuals across the AD continuum from the HEAD study[190 cognitively unimpaired elderly(CU), 109 with mild cognitive impairment(MCI), and 39 with dementia] with available FTP, MK6240, and plasma p ‐tau217 measured by ALZpath assay. A subset of 64 individuals(28 CU, 25 MCI, and 11 dementia) also had PI2620 and RO948, and p ‐tau217 measured by Lumipulse. The strength of the association was determined using t‐value maps from regression models testing the association between each tau PET tracer and plasma p ‐tau217, and the extent was measured by the percentage of significant voxels(t‐value>3.2). R‐square metric was used to determine how much of the variance in tau PET tracer estimates was explained by plasma p ‐tau217 concentrations. Associations between p ‐tau217 with tau PET were evaluated using the Spearman test. Result We found that in CU, both the extent and magnitude of the association with plasma p ‐tau217 were higher for MK6240 compared to FTP (Figure 1A‐D). Plasma p ‐tau217 explained a greater proportion of the variance in MK6240 than in FTP (Figure 1E‐F). In CI, the extent and magnitude of the association were similar for MK6240 and FTP. Additionally, plasma p ‐tau217 explained a similar proportion of the variance in MK6240 and FTP. Using the subset of individuals who had all tau tracers, MK6240 showed a slightly higher extent of association with p ‐tau217, followed by FTP, PI2620, and RO948 (Figure 2A‐B). The magnitude of association was stronger for MK6240, followed by PI2620, RO948, and FTP (Figure 2C‐D). Plasma p ‐tau217 explained a greater proportion of the variance in MK6240, followed by FTP, RO948, and PI2620 (Figure 2E‐F). We compared the associations between different p ‐tau217 assays, and both assays presented similar associations with all tau PET tracers (Figure 3). Conclusion In summary, our results indicate that the four tau PET tracers exhibit robust associations with plasma p ‐tau217 in similar topographical regions.